Statement of Comprehensive Income

Comprehensive income is the change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.

Gilead Sciences Inc., consolidated statement of comprehensive income

US$ in millions

12 months ended:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net income	480)	5,613)	4,566)	6,201)	89)
Net gain (loss) on foreign currency translation	(26)	60)	(11)	(38)	(2)
Net gain (loss) on available-for-sale debt securities	5)	28)	(29)	(6)	1)
Net gain (loss) on cash flow hedges	125)	(62)	(41)	187)	(144)
Other comprehensive income (loss), net	104)	26)	(81)	143)	(145)
Comprehensive income (loss), net	584)	5,639)	4,485)	6,344)	(56)
Comprehensive loss attributable to noncontrolling interest, net	—)	52)	26)	24)	34)
Comprehensive income (loss) attributable to Gilead, net	584)	5,691)	4,511)	6,368)	(22)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Comprehensive income item	Description	The company
Net income attributable to Gilead	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.	Gilead Sciences Inc. net income attributable to Gilead increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.
Comprehensive income (loss) attributable to Gilead, net	Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Exclude changes in equity resulting from investments by owners and distributions to owners.	Gilead Sciences Inc. comprehensive income (loss) attributable to Gilead, net increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.

Gilead Sciences Inc. (NASDAQ:GILD)

Statement of Comprehensive Income